Incyte to present Phase 1/2 VGA039 data in von Willebrand disease at ISTH Congress

Incyte Corporation

Incyte Corporation

INCY

0.00
  • Incyte will attend the ISTH 2026 Congress in Paris on July 11-15, 2026, featuring presentations tied to VGA039 in von Willebrand disease.
  • Phase 1/2 multidose results for VGA039 are scheduled for an oral session on July 13, 2026.
  • Additional VGA039 program presentations are set for July 13-14, 2026.
  • The event follows Incyte’s agreement to acquire Vega Therapeutics for USD 1.25 billion upfront, with up to USD 750 million in sales milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202606260900BIZWIRE_USPR_____20260625_BW529632) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.